Get started
JOHNSON & JOHNSONJOHNSON & JOHNSONJOHNSON & JOHNSON

JOHNSON & JOHNSON

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

JNJ trade ideas

Johnson & Johnson | Fundamental Analysis | MUST READ ⚡️The world's largest health care company is about to get a little smaller. Johnson & Johnson recently told investors that it intends to spin off its consumer health products business into a separate new company. If you've been considering these dividend-paying stocks for one reason or another, there's nothing wrong with the impending split. In fact, it makes the stock much more attractive. Here's a closer look at the company's plans so you can see why. Johnson & Johnson is a huge conglomerate with more than a hundred separate subsidiaries divided into three operating segments: pharmaceuticals, medical devices, and consumer health. Janssen, the company's pharmaceutical business, is the largest and fastest-growing of its subsidiaries. Pharmaceutical sales growth is outpacing the diverse medical devices segment, but the company wants to keep the two segments together. That's because convincing doctors to order knee replacement devices is not that much different than convincing doctors to prescribe a new cancer treatment. Johnson & Johnson practically created the consumer health care business more than 130 years ago, so at first, its division will seem strange. However, when the dust settles, the separation will likely benefit investors. The consumer healthcare segment is expected to generate about $15 billion in revenues in 2021, about 7 percent more than in 2020. The as-yet-unnamed new consumer health drug company will start with 20 different brands with annual sales of more than $150 million. The 7% growth rate that J&J expects this year in terms of underlying revenue for the consumer health segment is pretty good. Unfortunately, the comparison to 2020, when people made significantly fewer purchases, is a bit misleading. Not surprisingly, Johnson & Johnson wants to focus on pharmaceutical sales. Over the past five years, pharmaceutical sales have grown at an impressive rate of 9.2 percent a year. Over the same period, the company's other two segments have struggled to keep moving in the right direction. Revenue from the high-margin pharmaceutical segment also had a much stronger impact on the bottom line. In the third quarter, adjusted pre-tax income from the pharmaceutical segment was $5.7 billion. Pre-tax earnings from medical devices and consumer healthcare were $1.7 billion and $0.9 billion, respectively. If you're interested in buying Johnson & Johnson stock before it transforms into two companies, you have plenty of time to think it through. The company plans to complete the planned spin-off in 18 to 24 months. Shares of both new companies will initially have smaller payouts, but don't let that worry you. Dividend payments on both new shares are expected to be the same amount that shareholders will receive before the split. At recent prices, Johnson & Johnson stock offers an attractive yield of 3.1 percent, and investors can expect much higher returns on their initial investment in the future. The company is a dividend aristocrat that has not had a single year without a payout increase since the Kennedy administration. Johnson & Johnson's dividend program stands on such a solid foundation that steady increases in the coming years should not be a problem. Over the past 12 months, the company has used just 42% of the free cash flow generated by operations to pay dividends. It should be noted that these dividend-paying medical company stocks may not be suitable for every investor, especially those who are willing to take high risks in exchange for the chance to make huge profits. While it is unlikely that Johnson & Johnson will far outperform the broad market, investors can reasonably expect two steadily increasing dividend payments for years to come.
NYSE:JNJLong
by FOREXN1
7
Johnson & Johnson | Fundamental Analysis | Must Read...Johnson & Johnson is a leader in several areas of pharmaceutical research, including oncology and immunologic diseases. The company's portfolio of drugs in these two areas brings in billions of dollars in revenue each quarter. The company is currently seeking to strengthen its market share in COVID-19 vaccines. This year, Johnson & Johnson anticipates generating $2.5 billion from sales of its COVID-19 vaccine, well below the $33.5 billion and $20 billion, respectively, expected by Pfizer and Moderna. Fortuitously, some up-to-date developments favor Johnson & Johnson's ambitions in this profitable market. Most COVID vaccines currently available in the U.S. are given to patients in two doses about a month apart. J&J's vaccine is injected in only one dose. Based on real-world data and Phase 3 clinical trials, the company is sure that a single dose of its vaccine is 75% effective against severe cases of COVID for at least 28 days after vaccination. This efficacy compares disadvantageously with the effectiveness of vaccines marketed by Pfizer and Moderna, as well as a vaccine developed by Novavax, which has not yet received emergency use authorization (EUA) in the United States. All three vaccines have proven at least 90% effective in preventing COVID in clinical trials. Nevertheless, Johnson & Johnson recently revealed data showing that a booster dose (or second dose) of the vaccine, given two months after the first dose, improves its effectiveness to 94% against the onset of severe COVID. On Oct. 5, the company applied for EUA approval from the Food and Drug Administration (FDA) to administer a second dose of the vaccine. Then, on Oct. 15, a panel convened by the FDA voted unanimously for the agency to issue the company an EUA approval. The last wek, the FDA granted the company this long-awaited approval. In addition to getting the green light a little later than some of its competitors, Johnson & Johnson's COVID vaccine faced several obstacles. In mid-April, health authorities decided to suspend the distribution of the vaccine after it was suspected of causing blood clots in some patients (the original EUA approval was granted in late February). Regulators canceled that suspension about a week and a half later, arguing that the known benefits outweighed the known risks and requiring a new warning on the vaccine label going forward. Indeed, six patients out of more than 6.8 million vaccinated were known to have been affected by this adverse event. This episode is now left behind, but since the pandemic is not yet over, mainly because of the more dangerous delta variant of the virus, the need for vaccines remains. Since the second dose of the J&J vaccine seems to increase its effectiveness, this can only have a positive effect on its sales. This is especially true given that the FDA has not placed any health-related (or similar) restrictions on who can get a second dose of the vaccine from Johnson & Johnson. But here's the catch: the company has pledged not to profit from the product for the duration of the pandemic. In other words, boosted sales of vaccines will have no meaningful impact on the bottom line in the short term. In the future, the company may profit from its vaccine when the pandemic fades and if COVID becomes a seasonal disease like the flu, as some predict. But even then, given how competitive this market is, the J&J vaccine will have only a very moderate influence on a company that typically makes more than $10 billion in profits a year. In other words, investing in Johnson & Johnson because of its COVID vaccine is not a good idea. Luckily, there are plenty of other reasons for that. Consider the company's diversified operations. Its pharmaceutical business, the largest by revenue, includes quite a few blockbuster products whose sales continue to grow. Here are a few of them: in the third quarter (ended Sept. 30), revenue from the immunosuppressant Stelara was $2.4 billion, up 22.2% from the previous quarter. Oncology drug Darzalex increased its sales 43.7% year over year to $1.6 billion. This is just the tip of the iceberg for the company, with several dozen late-stage programs in development. Expanding its product line and approving new drugs is commonplace at Johnson & Johnson. Its consumer health products segment sells over-the-counter products with broad appeal, including Listerine, Neutrogena, Aveeno, and Tylenol. The company's medical device business adds to its revenue base. Here's another reason to invest in this company: the company has increased its dividend every year for more than 50 consecutive years, making it the Dividend King. The company currently has a yield of 2.53%, higher than the S&P 500 Index's 1.38%, and maintains a conservative cash payout ratio of 47%. That makes it engaging to income-seeking investors. In other words, Johnson & Johnson may not be the best stock to buy the COVID vaccine, but it remains a solid pharmaceutical company to invest in.
NYSE:JNJShort
by FOREXN1
3
Johnson & Johnson|Fundamental Analysis|Price action| MUST READ!In a nutshell, Johnson & Johnson's third-quarter results were generally good. The company reported a 10.7% year-over-year increase in revenue to $23.3 billion. Adjusted earnings per share rose 18.2% to $2.60, well above the consensus estimate of $2.35. Given the large earnings outperformance, you'd probably think the health care company's stock should have rallied Tuesday after the quarterly report was released. And you'd be right. J&J stock opened up about 1% and gained even more momentum during the day. Perhaps the rise would have been greater had it not been for the company's third-quarter earnings, which came in below analysts' average forecast of $23.7 billion. But there was more to this story for the health care giant than just the underlying numbers. Here are three things you might have missed about Johnson & Johnson's third-quarter results. First and foremost, three products accounted for 63% of the growth. Many investors love Johnson & Johnson largely because of its diversification. The company has three multi-billion dollar business segments targeting different areas of healthcare. Hundreds of products are sold in these segments. In 2020, J&J claimed 28 products or platforms with annual sales of more than $1 billion. Although Johnson & Johnson's business is broadly diversified, the drivers of its growth in the third quarter were not. Just three products accounted for about 63% of the company's total revenue growth. These products accounted for nearly 90% of J&J's pharmaceutical sales growth. Not surprisingly, the COVID-19 vaccine tops the list. It brought in $502 million in the third quarter, up from no revenue the previous year. The multiple myeloma drug Darzalex took a respectable second place. Sales of the drug totaled $1.58 billion in the third quarter, up 43.7% from nearly $1.1 billion in the same quarter in 2020. J&J's Stelara drug was the third-largest growth driver in the third quarter. Sales of the plaque psoriasis and psoriatic arthritis drug totaled $2.38 billion in the quarter. That's a 22.2% increase over sales of $1.95 billion in the previous quarter. Second, it's important to keep in mind that the COVID-19 pandemic continues to have a major impact beyond just the vaccine. Johnson & Johnson's COVID-19 vaccine certainly contributed significantly to the good third-quarter results. And it could make an even bigger furor in the future. J&J is likely to benefit significantly from booster sales (if, as expected, it gets approved for boosters). However, COVID-19 also continues to have a significant impact on J&J's fortunes beyond the vaccine. Johnson & Johnson's consumer health business, for example, has been helped by increased sales of the drug Tylenol. The company noted that some of the increase in sales of the over-the-counter drug was due to its use to relieve vaccine-induced symptoms. J&J also reported that sales of ORSL HCP electrolyte drinks increased due to relief of COVID-19 symptoms. It wasn't all good news, however. Sales bans in parts of the Asia-Pacific region had a negative impact on sales of baby care products. The company said growth in sales of its Imbruvica cancer drug was partially held back by COVID-19-related dynamics. In addition, sales of J&J's orthopedic medical products in the spine, sports, and other category fell mainly because of the impact of COVID-19 on the market. Finally, the company is now on the cusp of an international tipping point. Although based in the U.S., Johnson & Johnson has been a major competitor in global markets for most of its history. And now the health care giant is nearing a crucial international stage. In the third quarter, J&J's U.S. sales rose 7.9 percent year over year to just under $12 billion. Its international sales jumped 13.8% to $11.4 billion. International markets now account for 48.7% of total revenue. At the current rate of growth, by next year more than half of Johnson & Johnson's revenue will come from outside the United States. Investors should see this as a decidedly positive trend. Greater geographic diversification of revenues could make Johnson & Johnson even more stable than it is now.
NYSE:JNJShort
by FOREXN1
6
JONSON & JONSON D1The prices of shares of pharmaceutical companies have dropped significantly since the beginning of autumn. Like many other stock market assets. Today, the Coronovirus situation is starting to worsen! The number of patients and deaths is increasing every day. And this is not surprising. Because the vacation season is over and the inhabitants of the whole planet have gone to study and work. Increasing contact between people will certainly increase the number of sick people. Also, the onset of the cold season will contribute to new diseases. That will give an opportunity for pharmaceutical companies to make good profits. Johnson & Johnson also released a new drug for psoriasis. And he is actively working in other branches of medicine.
NYSE:JNJLong
by TradingForProfitPro
2